At close: June 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | -0.34 | -0.36 | -1.4 | 0 |
| Low Estimate | -0.34 | -0.36 | -1.4 | 0 |
| High Estimate | -0.34 | -0.36 | -1.4 | 0 |
| Year Ago EPS | -1.43 | -0.17 | -1.38 | -1.4 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.4 | -0.09 | -0.18 | 0 |
| EPS Actual | -1.43 | -0.17 | -0.12 | -0.34 |
| Difference | -1.03 | -0.08 | 0.06 | -0.34 |
| Surprise % | -257.50% | -88.90% | 33.30% | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.36 | -1.4 | 0 |
| 7 Days Ago | -0.34 | -0.36 | -1.4 | 0 |
| 30 Days Ago | -0.34 | -0.36 | -1.4 | 0 |
| 60 Days Ago | 0 | 0 | -0.92 | 0 |
| 90 Days Ago | 0 | 0 | -0.92 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | INTS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 76.20% | -- | -- | 7.80% |
| Next Qtr. | -111.80% | -- | -- | 11.00% |
| Current Year | -1.40% | -- | -- | 5.00% |
| Next Year | -- | -- | -- | 12.20% |
| Next 5 Years (per annum) | -- | -- | -- | 11.47% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 5/16/2024 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 3/21/2024 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 11/14/2023 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 8/24/2023 |
| Initiated | Benchmark: Speculative Buy | 7/18/2023 |
Related Tickers
PRTG Portage Biotech Inc.
0.2208
-5.03%
TRVI Trevi Therapeutics, Inc.
2.6100
-1.14%
ITOS iTeos Therapeutics, Inc.
14.62
-1.81%
LXEO Lexeo Therapeutics, Inc.
16.87
-0.76%
IKNA Ikena Oncology, Inc.
1.6800
0.00%
NAMS NewAmsterdam Pharma Company N.V.
19.67
+0.20%
ACHL Achilles Therapeutics plc
0.8681
+1.43%
ALA.AX Arovella Therapeutics Limited
0.1350
+3.85%
EPIX ESSA Pharma Inc.
4.8500
0.00%
2171.HK CARsgen Therapeutics Holdings Limited
5.030
+1.82%